CN112754014A - Composition for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof - Google Patents
Composition for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN112754014A CN112754014A CN202011604484.2A CN202011604484A CN112754014A CN 112754014 A CN112754014 A CN 112754014A CN 202011604484 A CN202011604484 A CN 202011604484A CN 112754014 A CN112754014 A CN 112754014A
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- water
- extracting solution
- green tea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 27
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 17
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 16
- 241001205401 Aspergillus cristatus Species 0.000 claims abstract description 64
- 244000269722 Thea sinensis Species 0.000 claims abstract description 35
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 34
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 34
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 31
- 240000008042 Zea mays Species 0.000 claims abstract description 31
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 31
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 30
- 235000009569 green tea Nutrition 0.000 claims abstract description 29
- 235000018597 common camellia Nutrition 0.000 claims abstract description 28
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 23
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 23
- 235000005822 corn Nutrition 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 15
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 12
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000009636 Huang Qi Substances 0.000 claims abstract description 6
- 229940107666 astragalus root Drugs 0.000 claims abstract description 6
- 240000001548 Camellia japonica Species 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 229920001218 Pullulan Polymers 0.000 claims description 14
- 239000004373 Pullulan Substances 0.000 claims description 14
- 235000019423 pullulan Nutrition 0.000 claims description 14
- 235000006533 astragalus Nutrition 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 10
- 241001061264 Astragalus Species 0.000 claims description 8
- 235000007244 Zea mays Nutrition 0.000 claims description 8
- 229940089639 cornsilk Drugs 0.000 claims description 8
- 210000004233 talus Anatomy 0.000 claims description 8
- 239000001231 zea mays silk Substances 0.000 claims description 8
- 241000045403 Astragalus propinquus Species 0.000 claims description 5
- 235000019206 astragalus extract Nutrition 0.000 claims description 5
- 241000219780 Pueraria Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 239000002994 raw material Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 241000209507 Camellia Species 0.000 abstract 3
- 238000012360 testing method Methods 0.000 description 21
- 238000000855 fermentation Methods 0.000 description 20
- 230000004151 fermentation Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000002775 capsule Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000009630 liquid culture Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002960 lipid emulsion Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 206010007688 Carotid artery thrombosis Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000519406 Paphiopedilum Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000009777 vacuum freeze-drying Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000020343 anhua dark tea Nutrition 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3562—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a preparation method of a composition for preventing and treating cardiovascular and cerebrovascular system diseases, which comprises the following steps: deactivating enzymes of fresh leaves of the golden camellia and fresh leaves of the green tea, and drying to obtain the treated golden camellia and green tea; preparing corn stigma extract, radix puerariae extract, radix astragali extract and dendrobium officinale extract; mixing the treated golden camellia and green tea, the corn stigma extracting solution, the kudzu root extracting solution, the astragalus root extracting solution, the dendrobium officinale extracting solution, coenzyme Q10, eurotium cristatum and auxiliary materials, drying and granulating to obtain the composition for preventing and treating cardiovascular and cerebrovascular system diseases. The preparation method disclosed by the invention is innovative in process, high in efficiency and low in cost, has remarkable effects of preventing and treating cardiovascular and cerebrovascular diseases by comprehensively reducing blood sugar and blood fat, resisting oxidation, regulating functions and enhancing immunity, and particularly has a novel breakthrough by applying synergy of eurotium cristatum hypha and coenzyme Q10, so that the health-care effect of the product is more remarkable, and the raw materials are all food-grade raw materials, so that the safety is extremely high.
Description
Technical Field
The invention belongs to the technical field of health-care food, and particularly relates to a composition for preventing and treating cardiovascular and cerebrovascular diseases and a preparation method thereof.
Background
With the improvement of living standard of people, cardiovascular and cerebrovascular diseases caused by hypertension, hyperlipidemia and hyperglycemia become the number one killer threatening the health of human beings. Japanese researchers process the golden flowers into health care products for preventing and treating three-high, the selling price of which exceeds gold, so that the health care function of eurotium cristatum is paid more and more attention and attention. However, the research on eurotium cristatum in China is mostly based on the influence of eurotium cristatum on tea, and the medical value of the eurotium cristatum serving as a probiotic with application potential in the medical field does not arouse sufficient attention of people and is not fully utilized and developed.
Coenzyme Q10 is a fat-soluble antioxidant, coenzyme Q10 is one of essential important elements for human life, can activate the nutrition of human cells and cell energy, has the functions of improving human immunity, enhancing antioxidation, delaying senility, enhancing human vitality and the like, and is widely used for cardiovascular system diseases in medicine.
The traditional Chinese medicine has advantages in the aspect of preventing and treating cardiovascular and cerebrovascular diseases, can effectively improve the disease condition, prevent and treat the disease development, has small toxic and side effects, but has longer treatment course, so that the invention is supplemented with eurotium cristatum and coenzyme Q10 on the basis of the traditional Chinese medicine, can effectively shorten the disease course for treatment, relieves the pain of patients, and can obviously improve the body function and reduce the occurrence of the diseases when being used by prevention people.
Disclosure of Invention
Aiming at the problems, the invention provides a composition for preventing and treating cardiovascular and cerebrovascular system diseases and a preparation method thereof.
Specifically, the present invention relates to the following aspects:
1. a preparation method of a composition for preventing and treating cardiovascular and cerebrovascular diseases is characterized by comprising the following steps:
deactivating enzymes of fresh leaves of the golden camellia and fresh leaves of the green tea, and drying to obtain the treated golden camellia and green tea;
preparing corn stigma extract, radix puerariae extract, radix astragali extract and dendrobium officinale extract;
mixing the treated golden camellia and green tea, the corn stigma extracting solution, the kudzu root extracting solution, the astragalus root extracting solution and the dendrobium officinale extracting solution, coenzyme Q10, eurotium cristatum and pullulan to obtain the composition for preventing and treating cardiovascular and cerebrovascular system diseases.
2. The preparation method according to claim 1, wherein the fresh golden camellia leaves are 16-24 parts by weight, the fresh green tea leaves are 0.4-1.2 parts by weight, the corn stigma is 4-12 parts by weight, the kudzu vine roots are 1-5 parts by weight, the astragalus membranaceus is 2-3 parts by weight, the dendrobium officinale is 0.6-1 part by weight, the eurotium cristatum hyphae is 0.4-0.6 part by weight, the coenzyme Q10 is 0.2-0.9 part by weight, and the pullulan is 0.002-0.008 part by weight.
3. The method according to any one of claims 1 to 3, wherein the water-removing comprises water-removing with a water-removing machine and water-removing with a microwave oven.
4. The preparation method according to the item 3, wherein the power of the microwave oven for de-enzyming is 460W-620W of middle fire, and the de-enzyming time is 60S-200S.
5. The preparation method according to the item 3, characterized in that the water-removing temperature of the water-removing machine is 110-120 ℃, and the water-removing time is 1-2 min.
6. The preparation method according to any one of items 1 to 5, wherein the drying comprises drying the de-enzymed golden camellia and green tea at 100 to 110 ℃ until the water content is 5 to 8 percent.
7. The method according to any one of claims 1 to 6, wherein the preparation of the corn silk extract and the pueraria root extract comprises the steps of: boiling the corn stigma, the radix puerariae and water together, and filtering to obtain the corn stigma extracting solution and the radix puerariae extracting solution.
8. The method according to any one of items 1 to 7, wherein the preparation of the radix astragali extract and the dendrobium officinale extract comprises the following steps: boiling the astragalus, the dendrobium officinale and water together, filtering, and treating filter residues with ethanol to obtain the astragalus extract and the dendrobium officinale extract.
9. The process according to any one of claims 1 to 8, wherein the taxonomic name of Eurotium cristatum is CGMCC No. 15398.
10. The composition for preventing and treating cardiovascular and cerebrovascular diseases, which is prepared by the preparation method of any one of items 1 to 9.
Compared with the prior art, the invention has the following beneficial effects:
(1) fresh leaves of golden camellia and fresh leaves of green tea are subjected to microwave enzyme deactivation, so that rich effective health-care active substance components such as tea polyphenol and the like are reserved to a greater extent;
(2) due to the slightly cold property of the golden camellia, the green tea and the dendrobium officinale, the formula is sweet and cool in flavor and mild in property, and is more beneficial to health care, fat reduction and blood sugar reduction of adults and old people;
(4) the corn stigma and the kudzuvine root are boiled and extracted by adding water, so that the effective ingredients of the corn stigma and the kudzuvine root can be fully extracted, the raw material residues can be removed, and the effective ingredients of the components are concentrated;
(5) the dendrobium officinale tender shoots and the astragalus membranaceus are extracted by water and ethanol, so that water-soluble and alcohol-soluble effective functional substances can be fully extracted, and the utilization rate of raw materials is improved;
(6) the Eurotium cristatum is subjected to liquid fermentation in a fermentation tank, the fermentation time is short, the activity is strong, the yield of the Eurotium cristatum is greatly improved compared with the traditional process, and the cost is reduced.
(7) All effective components are adhered and fully absorbed with the dry tea under the coordination of pullulan sugar, and then are pressed into tablets, decompressed and dried at low temperature and packaged into finished products. Here, pullulan plays a proper role in adhesion, and also helps to preserve freshness and quality of the finished product and protect probiotics.
In conclusion, the invention has the advantages of innovative process, improved efficiency and lower cost, and comprehensively reduces blood sugar and blood fat, resists oxidation, regulates functions and enhances immunity, so that the effect of preventing and treating cardiovascular and cerebrovascular diseases is obvious, the effect of preventing and treating the cardiovascular and cerebrovascular diseases can be prevented and can be particularly remarkable, and the application of the synergistic effect of the eurotium cristatum hypha and the coenzyme Q10 is a new breakthrough in the application of the raw materials of the formula, so that the health-care effect of the product is more obvious, and the raw materials are all food-grade raw materials, have extremely high safety, can be taken by public people for daily health care for preventing the cardiovascular and cerebrovascular diseases, and can also be used by patients suffering from the cardiovascular and cerebrovascular.
Detailed Description
The present invention is further illustrated by the following examples, which are intended to be purely exemplary of the invention and are not intended to be limiting.
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein can be used in experimental or practical applications, the materials and methods are described below. In case of conflict, the present specification, including definitions, will control, and the materials, methods, and examples are illustrative only and not intended to be limiting. The present invention is further illustrated by the following examples, which are not intended to limit the scope of the invention.
The invention provides a preparation method of a composition for preventing and treating cardiovascular and cerebrovascular system diseases, which comprises the following steps:
deactivating enzymes of fresh leaves of the golden camellia and fresh leaves of the green tea, and drying to obtain the treated golden camellia and green tea;
preparing corn stigma extract, radix puerariae extract, radix astragali extract and dendrobium officinale extract;
mixing the treated golden camellia and green tea, the corn stigma extracting solution, the kudzu root extracting solution, the astragalus root extracting solution and the dendrobium officinale extracting solution, coenzyme Q10, eurotium cristatum and pullulan to obtain the composition for preventing and treating cardiovascular and cerebrovascular system diseases.
Wherein, the functions of the raw materials in the method are as follows:
corn silk: the polysaccharide substance contained in the composition can promote the synthesis of liver glycogen, and has obvious blood pressure lowering effect as the corn silk for adjuvant treatment of diabetes, so people with low blood pressure should use the corn silk carefully. The corn stigma also has the effects of promoting urination, reducing swelling, accelerating blood coagulation and the like, and can be clinically used for treating various common diseases.
Kudzu root: the puerarin contained in the preparation can improve the sensitivity of insulin, remove free radicals in vivo and has obvious effect on improving the sugar metabolism of human bodies. Radix Puerariae also has peripheral blood vessel dilating effect, so it can help diabetic patients to prevent and treat peripheral neuropathy, retinopathy and renal function diseases caused by microangiopathy.
Green tea: the vitamin C, tea polyphenols, and catechin content and health promotion effect are high.
Astragalus root: astragalus polysaccharides can enhance insulin sensitivity by increasing glycogen synthase, insulin receptor activity, etc., and thus have a blood glucose lowering effect. Pharmacological research shows that: radix astragali has effects of inducing interferon and enhancing immunity, and can enhance disease resistance of organism and prevent various common diseases.
Dendrobium officinale: since ancient times, the dendrobium officinale is a special medicine for treating diabetes, is sweet in taste and slightly cold in nature, and has the effects of promoting the production of body fluid, nourishing the stomach, nourishing yin, clearing heat, moistening lung, tonifying kidney, improving eyesight and strengthening waist.
Eurotium cristatum hyphae: belongs to probiotics, is natural thallus grown by the 'flower growing' process of Anhua dark tea, has stronger effects of reducing blood fat, reducing blood pressure, regulating carbohydrate metabolism and the like, and greatly improves the yield by utilizing high-density fermentation of fermentation tank liquid.
Coenzyme Q10: coenzyme Q10 helps to provide sufficient oxygen to the heart muscle and prevent sudden heart disease, and coenzyme Q10 plays a key role especially during myocardial hypoxia. The coenzyme Q10 is supplemented to patients with heart disease, periodontitis, gastrointestinal ulcer, senile dementia and diabetes, and helps to improve the condition.
Pullulan: the industrial polysaccharide is prepared by directly fermenting starch hydrolysate, sucrose or other saccharides, has smooth and refreshing feeling in water solution, and has the functions of improving taste, proliferating bifidobacterium, treating constipation, and keeping freshness.
The Eurotium cristatum is classified and named as Eurotium cristatum, is preserved in China general microbiological culture Collection center (CGMCC) at 4 and 2 days in 2018, has the preservation number of CGMCC NO.15398, and has the preservation address of No. 3 of No.1 Xilu north Chen in the sunward area of Beijing.
Example 1
A preparation method of a composition for preventing and treating cardiovascular and cerebrovascular diseases, wherein the raw materials used in the method comprise:
fresh leaves of golden camellia 16 parts
Corn silk 4 parts
1 part of kudzu root
Fresh green tea leaf 0.8 parts
Dendrobium officinale tender shoot 0.8 parts
2 portions of astragalus root
0.5 portion of coronary disease sporangium hypha
100.4 portions of coenzyme Q
0.002 part of pullulan
Specifically, the preparation method comprises the following steps:
(1) de-enzyming 16kg of fresh leaves of the golden camellia and 0.8kg of fresh leaves of the green tea by using a de-enzyming machine, wherein the de-enzyming temperature is 110 ℃, the de-enzyming time is 2min, and drying at 100 ℃ after de-enzyming until the water content is 5-8% to obtain the treated golden camellia and the green tea;
(2) putting 4kg of corn stigma and 1kg of radix puerariae into a decocting pot, adding 20kg of water, boiling for 30min, and filtering with 200 meshes to obtain a corn stigma extracting solution and a radix puerariae extracting solution, wherein the two extracting solutions are mixed together;
(3) cutting 2kg of astragalus and 0.8kg of dendrobium officinale tender shoots, putting the cut materials into a decocting pot, adding 15kg of water, boiling for 60min, filtering the mixture through a 200-mesh sieve to obtain a decoction liquid, adding 90% (V/V) ethanol which is 2 times of the weight of the filter residue into the filter residue, uniformly stirring the mixture, soaking the mixture for 30 hours, filtering the mixture to remove the residue, and distilling the filtrate to recover the ethanol to obtain an astragalus extract and a dendrobium officinale extract;
(4) obtaining eurotium cristatum hyphae:
a. activating eurotium cristatum strains: and (3) performing aseptic inoculation in a clean bench by using a solid PDA culture medium, and then placing the test tube in an incubator at 30 ℃ for static culture for 104h to obtain the activated eurotium cristatum strain.
b. C, shaking culture of eurotium cristatum: and (b) inoculating the activated eurotium cristatum colony in the step a into a 500ml shake flask filled with 200ml of liquid culture medium, and placing the shake flask in a shaking table at the temperature of 30 ℃ for culturing for 96h to obtain eurotium cristatum seed liquid.
c. Performing high-density fermentation on eurotium cristatum in a fermentation tank; and c, inoculating the eurotium cristatum seed liquid obtained in the step b into a liquid culture medium according to the inoculation amount of 20% (V/V) for high-density fermentation culture, wherein the culture temperature is 30 ℃, the pH value is 5.0, the dissolved oxygen is controlled to be 50-80%, and the fermentation is stopped when the hypha amount is not increased any more.
d. Collecting Eurotium cristatum mycelium, filtering the obtained Eurotium cristatum liquid with 8 layers of gauze, collecting mycelium in the fermentation product, washing the mycelium with distilled water for 3-5 times, removing water as much as possible, and freeze-drying the mycelium in a vacuum freeze-drying machine to obtain the Eurotium cristatum mycelium.
(5) Coenzyme Q10: purchased from GNC/jianhanxi usa, 100mg x 120 pellets, production lot number: 3146FR 7853;
(6) adding 0.002kg of pullulan into the components obtained in the steps (2), (3) and (4), and uniformly stirring to obtain a mixture;
(7) uniformly mixing the treated golden camellia and green tea obtained in the step (1) with the mixture obtained in the step (6) to obtain a composition;
(8) and (3) pressing the composition obtained in the step (7) into tablets by using a pharmaceutical tablet press, wherein the tablets are 0.2g per tablet, and then drying and packaging under reduced pressure at 30-35 ℃ to obtain the health-care product for preventing and treating cardiovascular and cerebrovascular system diseases.
Example 2
A preparation method of a composition for preventing and treating cardiovascular and cerebrovascular diseases, wherein the raw materials used in the method comprise:
fresh leaves of golden camellia 18 parts
5 portions of corn silk
2 portions of kudzu root
1 part of fresh green tea leaves
Dendrobium officinale tender shoot 0.8 parts
2.5 parts of astragalus
0.5 portion of coronary disease sporangium hypha
100.5 portions of coenzyme Q
0.003 portion of pullulan
Specifically, the preparation method comprises the following steps:
(1) deactivating enzyme of 18kg of fresh leaves of the golden camellia and 1kg of fresh leaves of the green tea by using a water-removing machine at the temperature of 120 ℃ for 1min, and drying at the temperature of 110 ℃ after deactivation of enzyme until the water content is 5-8% to obtain the treated golden camellia and the treated green tea;
(2) putting 5kg of corn stigma and 2kg of radix puerariae into a decocting pot, adding 24kg of water, boiling for 30min, and filtering with 200 meshes to obtain a corn stigma extracting solution and a radix puerariae extracting solution, wherein the two extracting solutions are mixed together;
(3) cutting 2.5kg of astragalus and 0.8kg of dendrobium officinale tender shoots, putting the cut materials into a decocting pot, adding 18kg of water, boiling for 60min, filtering through a 200-mesh sieve to obtain a decoction liquid, adding 2 times of 90% (V/V) ethanol by weight of filter residues, uniformly stirring, soaking for 30 hours, filtering to remove residues, taking filtrate, distilling and recovering the ethanol to obtain an astragalus extract and a dendrobium officinale extract;
(4) obtaining hypha of eurotium cristatum:
a. activating eurotium cristatum strains: and (3) performing aseptic inoculation in a clean bench by using a solid PDA culture medium, and then placing the test tube in an incubator at 30 ℃ for static culture for 104h to obtain the activated eurotium cristatum strain.
b. C, shaking culture of eurotium cristatum: and (b) inoculating the activated eurotium cristatum colony in the step a into a 500ml shake flask filled with 200ml of liquid culture medium, and placing the shake flask in a shaking table at the temperature of 30 ℃ for culturing for 96h to obtain eurotium cristatum seed liquid.
c. Performing high-density fermentation on eurotium cristatum in a fermentation tank; and c, inoculating the eurotium cristatum seed liquid obtained in the step b into a liquid culture medium according to the inoculation amount of 20% (V/V) for high-density fermentation culture, wherein the culture temperature is 30 ℃, the pH value is 5.0, the dissolved oxygen is controlled to be 50-80%, and the fermentation is stopped when the hypha amount is not increased any more.
d. Collecting Eurotium cristatum mycelium, filtering the obtained Eurotium cristatum liquid with 8 layers of gauze, collecting mycelium in the fermentation product, washing the mycelium with distilled water for 3-5 times, removing water as much as possible, and freeze-drying the mycelium in a vacuum freeze-drying machine to obtain the Eurotium cristatum mycelium.
(5) Coenzyme Q10: purchased from GNC/jianhanxi usa, 100mg x 120 pellets, production lot number: 3146FR 7853;
(6) adding 0.003kg of pullulan into the components obtained in the steps (2), (3), (4) and (5), and uniformly stirring to obtain a mixture;
(7) uniformly mixing the treated golden camellia and green tea obtained in the step (1) with the mixture obtained in the step (6) to obtain a composition;
(8) and (3) pressing the composition obtained in the step (7) into tablets by using a pharmaceutical tablet press, wherein the tablets are 0.2g per tablet, and then drying and packaging under reduced pressure at 30-35 ℃ to obtain the health-care product for preventing and treating cardiovascular and cerebrovascular system diseases.
Example 3
A preparation method of a composition for preventing and treating cardiovascular and cerebrovascular diseases, wherein the raw materials used in the method comprise:
fresh leaves of golden camellia 20 parts
6 portions of corn silk
2 portions of kudzu root
1 part of fresh green tea leaves
1.0 part of dendrobium officinale tender shoots
2.0 parts of astragalus
0.5 portion of coronary disease sporangium hypha
100.6 portions of coenzyme Q
0.005 part of pullulan
Specifically, the preparation method comprises the following steps:
(1) deactivating enzyme of 20kg of fresh golden camellia leaves and 1.0kg of fresh green tea leaves by using a microwave oven, wherein the power of middle fire is 530W, the deactivation time is 100S, and drying at 100-110 ℃ after deactivation to obtain dry tea leaves, wherein the water content is 5-8%;
(2) putting 6kg of corn stigma and 2kg of radix puerariae into a decocting pot, adding 32kg of water, boiling for 30min, and filtering with 200 meshes to obtain a corn stigma extracting solution and a radix puerariae extracting solution, wherein the two extracting solutions are mixed together;
(3) cutting 2.0kg of astragalus and 1.0kg of dendrobium officinale tender shoots, putting the cut materials into a decocting pot, adding 18kg of water, boiling for 60min, filtering through a 200-mesh sieve to obtain a decoction liquid, adding 2 times of 90% (V/V) ethanol by weight of filter residues, uniformly stirring, soaking for 30 hours, filtering to remove residues, taking filtrate, distilling and recovering the ethanol to obtain an astragalus extract and a dendrobium officinale extract;
a. activating eurotium cristatum strains: and (3) performing aseptic inoculation in a clean bench by using a solid PDA culture medium, and then placing the test tube in an incubator at 30 ℃ for static culture for 104h to obtain the activated eurotium cristatum strain.
b. C, shaking culture of eurotium cristatum: and (b) inoculating the activated eurotium cristatum colony in the step a into a 500ml shake flask filled with 200ml of liquid culture medium, and placing the shake flask in a shaking table at the temperature of 30 ℃ for culturing for 96h to obtain eurotium cristatum seed liquid.
c. Performing high-density fermentation on eurotium cristatum in a fermentation tank; and c, inoculating the eurotium cristatum seed liquid obtained in the step b into a liquid culture medium according to the inoculation amount of 20% (V/V) for high-density fermentation culture, wherein the culture temperature is 30 ℃, the pH value is 5.0, the dissolved oxygen is controlled to be 50-80%, and the fermentation is stopped when the hypha amount is not increased any more.
d. Collecting Eurotium cristatum mycelium, filtering the obtained Eurotium cristatum liquid with 8 layers of gauze, collecting mycelium in the fermentation product, washing the mycelium with distilled water for 3-5 times, removing water as much as possible, and freeze-drying the mycelium in a vacuum freeze-drying machine to obtain the Eurotium cristatum mycelium.
(5) Coenzyme Q10: purchased from GNC/jianhanxi usa, 100mg x 120 pellets, production lot number: 3146FR 7853;
(6) adding 0.005kg of pullulan into the components obtained in the steps (2), (3), (4) and (5), and uniformly stirring to obtain a mixture;
(7) uniformly mixing the dried tea leaves obtained in the step (1) and the mixture obtained in the step (6) to obtain a composition;
(8) and (3) pressing the composition obtained in the step (7) into tablets by using a pharmaceutical tablet press, wherein the tablets are 0.2g per tablet, and then drying and packaging under reduced pressure at 30-35 ℃ to obtain the health-care product for preventing and treating cardiovascular and cerebrovascular system diseases.
Test example 1: pharmacodynamic experiment of in vivo thrombosis in mice treatment experiment:
the test animals were: SPF grade male mice, 70, weighing 23-28 g, were randomly divided into 7 groups of 10 mice each. The test mice were prepared from the experimental animals of slagoka, Hunan province, Inc.; feeding conditions are as follows: in an SPF animal laboratory, the room temperature is 23-25 ℃, the relative humidity is 40-70%, illumination/darkness is alternated for 12 hours, and free ingestion and drinking are realized.
And (3) preparing a sample: tablets of the compositions prepared in example 1, example 2, example 3, 0.2 g/tablet, homemade;
0.2g of eurotium cristatum hypha tablets per tablet are prepared, the content of eurotium cristatum hypha in each tablet is the same as that in examples 1, 2 and 3, and sodium carboxymethylcellulose, microcrystalline cellulose and sodium carboxymethyl starch magnesium stearate are also contained;
coenzyme Q10 capsules, purchased from GNC/jiannanxi, usa, 100mg x 120 capsules, production lot number: 3146FR 7853;
the traditional Chinese medicine decoction is self-made, and the preparation method is the same as that in example 3, except that no paphiopedilum hirsutum hypha and coenzyme Q10 are added, and only other components are contained.
Administration dose: the drugs and dosages administered to each test group are shown in table 1;
the test method comprises the following steps: according to the administration dose listed in Table 1, 0.1mg of each of the collagen-epinephrine mixed thrombus-inducing agents was injected into the tail vein 1 hours after the intragastric administration. Recording the hemiplegia recovery data of the mice within 20min after injection, calculating the thrombosis protection rate of the mice of each administration group (death protection rate is the death number of a control group-the death number of the administration group/the death number of the control group), and obtaining the result according to the formula q is EAB/(EA+EB-EA*EB) The q values of each group were obtained.
Test results and conclusions: the test results are shown in Table 1. The results show that the composition tablets have a protective effect on collagen-epinephrine-induced cerebral thrombosis death of mice (the effect of the composition tablets prepared in example 3 is optimal), and are higher than the effects of corresponding eurotium cristatum mycelium tablets, coenzyme Q10 capsules and traditional Chinese medicine decoction which are independently used. Probability addition indicates that the edible Eurotium cristatum hyphae, the coenzyme Q10 capsule and the traditional Chinese medicine are compatible according to the formula shown in example 3, the efficacy is enhanced, and the synergistic effect is achieved.
Table 1: pharmacodynamic experimental data (n ═ 10) of thrombosis in vivo of test sample treated mice experiment
Test example 2: effect of sample to be tested on thrombosis time of experimental common carotid artery of rat
The test animals were: male SPF and SD rats, 140, weighing 200-220 g, were randomly divided into 7 groups of 20 rats each. The test animals were obtained from the experimental animals of slagoka, Hunan; feeding conditions are as follows: in an SPF animal laboratory, the room temperature is 23-25 ℃, the relative humidity is 40-70%, illumination/darkness is alternated for 12 hours, and free ingestion and drinking are realized.
And (3) preparing a sample: tablets of the compositions prepared in example 1, example 2, example 3, 0.2 g/tablet;
0.2g of eurotium cristatum hypha tablets per tablet are prepared, the content of eurotium cristatum hypha in each tablet is the same as that in examples 1, 2 and 3, and sodium carboxymethylcellulose, microcrystalline cellulose and sodium carboxymethyl starch magnesium stearate are also contained;
coenzyme Q10 capsules, purchased from GNC/jiannanxi, usa, 100mg x 120 capsules, production lot number: 3146FR 7853;
the traditional Chinese medicine decoction is self-made, and the preparation method is the same as that in example 3, except that no paphiopedilum hirsutum hypha and coenzyme Q10 are added, and only other components are contained.
Administration dose: 30mg/kg (30 ul/kg).
The test method comprises the following steps: rats were anesthetized with 2.5% sodium pentobarbital (25mg/kg) by intraperitoneal injection, fixed in the supine position, the right common carotid artery was isolated, the carotid artery was subjected to an intra-carotid artery current injury membrane method, and the carotid artery thrombosis time of different groups of animals was measured with a BT87-3 experimental in vivo thrombometer. The stimulation click and temperature probe are applied to the common carotid artery according to the table 2, stimulation is started 10min after administration, the stimulation intensity is 2mA, the stimulation switch is closed after 5min of stimulation, the electrode is taken down, the temperature control meter is adjusted to zero after 3min, the sudden drop time of the carotid artery temperature is observed, the time from the beginning of electrical stimulation to the sudden drop of the aorta temperature is recorded, and the time is determined as the carotid artery thrombosis forming time (3000 seconds for over 3000 seconds).
Test results and conclusions: the test results are shown in Table 2. The results show that: the tablet administration group, the sporangium coronarium mycelium tablet administration group, the coenzyme Q10 capsule administration group and the Chinese medicinal decoction administration group of the compositions prepared in example 1, example 2 and example 3 all delayed the arterial thrombosis time compared with the control group. It is shown that the tablet administration group, the eurotium cristatum hypha tablet administration group, the coenzyme Q10 capsule administration group and the traditional Chinese medicine decoction administration group of the compositions prepared in example 1, example 2 and example 3 have a protective effect on experimental arterial thrombosis of rats. Moreover, the effect of the composition tablet group prepared in example 3 is better than that of the eurotium cristatum hypha tablet administration group, the coenzyme Q10 capsule administration group and the traditional Chinese medicine decoction administration group, and a synergistic effect is suggested.
Table 2: effect of test sample on experimental common carotid thrombosis time in rats (n ═ 10):
test example 3: influence of sample to be tested on experimental hyperlipidemia of rats
The test animals were: 140 SPF SD rats with half male and female bodies and weight of 200-230 g are produced by Schlekschada laboratory animals Co., Ltd, Hunan province; feeding conditions are as follows: in an SPF animal laboratory, the room temperature is 23-25 ℃, the relative humidity is 40-70%, illumination/darkness is alternated for 12 hours, and free ingestion and drinking are realized.
And (3) preparing a sample: tablets of the compositions prepared in example 1, example 2, example 3, 0.2 g/tablet;
0.2g of eurotium cristatum hypha tablets per tablet are prepared, the content of eurotium cristatum hypha in each tablet is the same as that in examples 1, 2 and 3, and sodium carboxymethylcellulose, microcrystalline cellulose and sodium carboxymethyl starch magnesium stearate are also contained;
coenzyme Q10 capsules: purchased from GNC/jianhanxi usa, 100mg x 120 pellets, production lot number: 3146FR 7853;
the traditional Chinese medicine decoction is self-made, and the preparation method is the same as that in example 3, except that no paphiopedilum hirsutum hypha and coenzyme Q10 are added, and only other components are contained.
Administration dose: 30mg/kg (30 ul/kg).
Reagents and instruments: the total cholesterol and triglyceride test box is purchased from Nanjing institute of bioengineering; model 7150 full-automatic biochemical analyzer (Hitachi, Japan).
The test method comprises the following steps: 140 SD rats were randomly allocated 20 out for blank control, and the remaining 120 were used for model replication. Referring to the literature, "comparative study of lipid emulsion for establishing hyperlipidemia model mice" (Zhoujia Hao Zhao Luoyongyan Zonce nan), high-fat emulsion (wherein, the high-fat emulsion contains 10% cholesterol, 20% lard, 2% sodium cholate, 1% propylthiouracil, 20% methyl sorbitol, and 20% propylene glycol) was prepared, and the high-fat emulsion was administered by gavage at a rate of 10ml/kg, and physiological saline was administered by gavage at blank control group 1 time per day for 3 consecutive weeks. And (3) cutting the tail and taking blood, measuring the serum TC value, and successfully copying by taking the model that the TC value is obviously higher than that of a blank control group as the model, namely the hyperlipemia model rat.
Grouping and administration: except for the blank control group (constant volume saline), 120 hyperlipemia model rats were randomly divided into 6 groups according to body weight and sex, namely the model group (constant volume saline) and the other 6 groups were gavaged at 30mg/kg (30ul/kg), 1 time per day for 28 days.
Measurement of the index: blood is collected from the orbit after the last administration, serum is separated, and triglyceride levels in the serum are detected by using the kit.
Test results and conclusions: the test results are shown in tables 3 and 4. The results show that: the composition tablet administration group, the eurotium cristatum hypha tablet administration group, the coenzyme Q10 capsule administration group and the traditional Chinese medicine decoction administration group prepared in the embodiments 1, 2 and 3 can effectively reduce the blood lipid cholesterol and triglyceride of the rats with the eating hyperlipidemia, and the composition tablet prepared by the compatibility of the embodiment 3 has the best effect, which shows that the compatibility of the edible eurotium cristatum hypha, the coenzyme Q10 capsule and the traditional Chinese medicine components as shown in the embodiment 3 enhances the drug effect and has a synergistic effect.
Table 3: effect of sample to be tested on serum Cholesterol in rats with dietary hyperlipemia (n ═ 10)
Table 4: effect of sample to be tested on dietary hyperlipemia rat serum triglyceride (n ═ 10)
Claims (10)
1. A preparation method of a composition for preventing and treating cardiovascular and cerebrovascular diseases is characterized by comprising the following steps:
deactivating enzymes of fresh leaves of the golden camellia and fresh leaves of the green tea, and drying to obtain the treated golden camellia and green tea;
preparing corn stigma extract, radix puerariae extract, radix astragali extract and dendrobium officinale extract;
mixing the treated golden camellia and green tea, the corn stigma extracting solution, the kudzu root extracting solution, the astragalus root extracting solution and the dendrobium officinale extracting solution, coenzyme Q10, eurotium cristatum and pullulan to obtain the composition for preventing and treating cardiovascular and cerebrovascular system diseases.
2. The preparation method according to claim 1, wherein the fresh golden camellia leaves are 16-24 parts by weight, the fresh green tea leaves are 0.4-1.2 parts by weight, the corn stigma is 4-12 parts by weight, the kudzu vine roots are 1-5 parts by weight, the astragalus membranaceus is 2-3 parts by weight, the dendrobium officinale is 0.6-1 part by weight, the eurotium cristatum hyphae is 0.4-0.6 part by weight, the coenzyme Q10 is 0.2-0.9 part by weight, and the pullulan is 0.002-0.008 part by weight.
3. The method according to any one of claims 1 to 3, wherein the water-removing includes a water-removing machine water-removing and a microwave oven water-removing.
4. The preparation method according to claim 3, wherein the microwave oven has a water-removing power of 460W-620W and a water-removing time of 60S-200S.
5. The preparation method according to claim 3, wherein the water-removing temperature of the water-removing machine is 110-120 ℃, and the water-removing time is 1-2 min.
6. The preparation method according to any one of claims 1 to 5, wherein the drying comprises drying the de-enzymed golden camellia and green tea at 100 to 110 ℃ to a moisture content of 5 to 8%.
7. The method according to any one of claims 1 to 6, wherein the preparation of the corn silk extract and the pueraria root extract comprises the steps of: boiling the corn stigma, the radix puerariae and water together, and filtering to obtain the corn stigma extracting solution and the radix puerariae extracting solution.
8. The method for preparing the extract liquid of the astragalus membranaceus and the extract liquid of the dendrobium officinale as claimed in any one of claims 1 to 7, wherein the preparation method of the extract liquid of the astragalus membranaceus and the extract liquid of the dendrobium officinale comprises the following steps: boiling the astragalus, the dendrobium officinale and water together, filtering, and treating filter residues with ethanol to obtain the astragalus extract and the dendrobium officinale extract.
9. The method according to any one of claims 1 to 8, wherein the taxonomic name of Eurotium cristatum is CGMCC NO. 15398.
10. The composition for preventing and treating cardiovascular and cerebrovascular diseases, which is prepared by the preparation method of any one of claims 1-9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011604484.2A CN112754014A (en) | 2020-12-29 | 2020-12-29 | Composition for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011604484.2A CN112754014A (en) | 2020-12-29 | 2020-12-29 | Composition for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112754014A true CN112754014A (en) | 2021-05-07 |
Family
ID=75697376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011604484.2A Pending CN112754014A (en) | 2020-12-29 | 2020-12-29 | Composition for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112754014A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117801967A (en) * | 2024-03-01 | 2024-04-02 | 烟台市供销社茶业有限公司 | Method for culturing Eurotium cristatum and application |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103734696A (en) * | 2013-11-21 | 2014-04-23 | 荣成百合生物技术有限公司 | Softgel for improving immunity and protecting internal organs, and preparation method thereof |
| CN104857034A (en) * | 2015-04-14 | 2015-08-26 | 南京贝杉国际贸易有限公司 | Functional food for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN105055897A (en) * | 2015-07-13 | 2015-11-18 | 陈树杰 | Health tea tablet capable of preventing and treating diabetes and preparation method of health tea tablet |
| CN106138831A (en) * | 2016-08-18 | 2016-11-23 | 北华大学 | A kind of Chinese medicine composition treating cardiovascular and cerebrovascular disease and preparation method thereof |
| CN106581492A (en) * | 2016-12-30 | 2017-04-26 | 孝感华越机电科技有限公司 | Traditional Chinese medicine for treatment of diabetes |
| CN106729675A (en) * | 2016-04-24 | 2017-05-31 | 佛山瑞箭体育器材有限公司 | It is a kind of to treat pharmaceutical composition of cardiovascular and cerebrovascular disease and preparation method thereof |
| US20170354700A1 (en) * | 2014-12-30 | 2017-12-14 | Shineway Pharmaceutical Group Ltd. | Chinese medicinal composition for preventing or treating cardiovascular and cerebrovascular diseases or dementia, and preparation method and use thereof |
| CN111803528A (en) * | 2020-08-20 | 2020-10-23 | 西安巨子生物基因技术股份有限公司 | Eurotium cristatum product and application thereof |
-
2020
- 2020-12-29 CN CN202011604484.2A patent/CN112754014A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103734696A (en) * | 2013-11-21 | 2014-04-23 | 荣成百合生物技术有限公司 | Softgel for improving immunity and protecting internal organs, and preparation method thereof |
| US20170354700A1 (en) * | 2014-12-30 | 2017-12-14 | Shineway Pharmaceutical Group Ltd. | Chinese medicinal composition for preventing or treating cardiovascular and cerebrovascular diseases or dementia, and preparation method and use thereof |
| CN104857034A (en) * | 2015-04-14 | 2015-08-26 | 南京贝杉国际贸易有限公司 | Functional food for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN105055897A (en) * | 2015-07-13 | 2015-11-18 | 陈树杰 | Health tea tablet capable of preventing and treating diabetes and preparation method of health tea tablet |
| CN106729675A (en) * | 2016-04-24 | 2017-05-31 | 佛山瑞箭体育器材有限公司 | It is a kind of to treat pharmaceutical composition of cardiovascular and cerebrovascular disease and preparation method thereof |
| CN106138831A (en) * | 2016-08-18 | 2016-11-23 | 北华大学 | A kind of Chinese medicine composition treating cardiovascular and cerebrovascular disease and preparation method thereof |
| CN106581492A (en) * | 2016-12-30 | 2017-04-26 | 孝感华越机电科技有限公司 | Traditional Chinese medicine for treatment of diabetes |
| CN111803528A (en) * | 2020-08-20 | 2020-10-23 | 西安巨子生物基因技术股份有限公司 | Eurotium cristatum product and application thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117801967A (en) * | 2024-03-01 | 2024-04-02 | 烟台市供销社茶业有限公司 | Method for culturing Eurotium cristatum and application |
| CN117801967B (en) * | 2024-03-01 | 2024-04-30 | 烟台市供销社茶业有限公司 | Method for culturing Eurotium cristatum and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102669667B (en) | Health food with dual functions of protecting liver and adjusting blood fat and preparation method thereof | |
| CN103493941B (en) | A kind of Weight-reducing health-care tea and preparation method thereof | |
| CN102613330B (en) | Fermented red yeast tea and extract, extract composition and preparation method thereof | |
| CN101502627B (en) | Chinese medicine health product preparation for preventing and treating alcoholic liver disease and preparation method thereof | |
| CN103740566B (en) | Rosa roxbunghii medicinal liquor and preparation method thereof | |
| KR20130056639A (en) | Health food fermented using effective micro-organisms with herbal medicine for reducing blood sugar and blood pressure and manufacturing method thereof | |
| CN108671002B (en) | Composition containing saussurea involucrate culture extract and application thereof | |
| CN104957305A (en) | Ficus hispida fruit compounded tea tablets capable of reducing blood glucose and preparation method for ficus hispida fruit compounded tea tablet | |
| CN102613331B (en) | Halimasch fermented tea and halimasch fermented tea composition, and preparation methods thereof | |
| CN103055157B (en) | Compound dendrobium huoshanense, cistanche and ganoderma granules and production process thereof | |
| CN102894364A (en) | Preparation method of balsam pear/green tea sugar-reducing buccal tablets | |
| CN112754014A (en) | Composition for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN105055897A (en) | Health tea tablet capable of preventing and treating diabetes and preparation method of health tea tablet | |
| CN107494817A (en) | A kind of hypoglycemic tea | |
| CN107019136A (en) | A kind of solid beverage with effect of lowering blood sugar and preparation method thereof | |
| CN106581166A (en) | Anti-fatigue food, health product or pharmaceutical composition | |
| CN102488744A (en) | Medicament for relieving alcohol toxicity and preparation method thereof | |
| CN105831318A (en) | Polypeptide tea for blood glucose reduction and manufacturing method of polypeptide tea | |
| CN101569645A (en) | Smallanthus sonchifolius buccal tablet and preparation method thereof | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN105713787B (en) | A kind of preparation method of liver-protecting type safflower pueraria lobata yellow rice wine | |
| CN108260682A (en) | A kind of hypoglycemic, reducing blood lipid and the health protection tea of blood pressure lowering | |
| CN108813500B (en) | Health-preserving honey paste with effects of tonifying middle-jiao and Qi, nourishing blood and soothing nerves and regulating human body functions | |
| CN107495340A (en) | A kind of anti-trioxypurine diuretic compositions and preparation method thereof | |
| CN103343078A (en) | Production process of golden stichopus japonicus health-care yellow wine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210507 |